RecruitingPhase 1NCT06889168

Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)

Studying Lymphangioleiomyomatosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Columbia University
Principal Investigator
Jeanine D'Armiento, MD, PhD
Columbia University
Intervention
Imatimib Mesylate(drug)
Enrollment
20 enrolled
Eligibility
18-64 years · FEMALE
Timeline
20252027

Study locations (2)

Collaborators

United States Department of Defense · Medical University of South Carolina

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06889168 on ClinicalTrials.gov

Other trials for Lymphangioleiomyomatosis

Additional recruiting or active studies for the same condition.

See all trials for Lymphangioleiomyomatosis

← Back to all trials